, /PRNewswire/ -- Floreo, a pioneering developer of virtual reality (VR)-based therapy for neurodivergent youth and adults, is proud to announce its inaugural scientific advisory board. Comprising six leaders across behavioral health research, clinical practice, and healthcare delivery, the board is chaired by Dr. Paula Pompa-Craven, chief clinical officer of Easterseals Southern California--the largest provider of disability services in California.

"There is a real urgency and demand for accessible, effective, and evidence-based interventions that can serve individuals living with autism. We see a tremendous opportunity for collaboration across the scientific, clinical, and technology communities. Early evidence suggests tremendous promise for virtual reality as a vehicle for therapeutic support, and we're honored to collaborate with such distinguished experts to ensure our work is grounded in clinical rigor," said Vijay Ravindran, CEO and founder of Floreo. "Their research and insights will help guide the continued development of our technology to better serve the neurodiverse community."

Utilized in both clinical and school settings, Floreo's immersive VR lessons support the development of social, behavioral, communication, emotional regulation, and life skills for individuals with Autism Spectrum Disorder, ADHD, and other diagnoses. In 2023, Floreo became the first VR autism technology to receive the Food and Drug Administration's (FDA) breakthrough device designation.

The scientific advisory board will provide strategic direction on research initiatives, clinical study design, and the continued scientific validation of Floreo's VR-based learning tools. The board convened for its first meeting at the Association for Behavior Analysis International (ABAI) conference and will serve as a guiding pillar for Floreo's growing research portfolio.

Founding members of the scientific advisory board include:

Shirley Mak-Parisi, Vice President of Clinical Affairs, Floreo

• Shirley Mak-Parisi is a clinical research professional with over 20 years of experience. Prior to joining Floreo, Shirley led clinical operations for medical device companies and behavioral health tech startups. She has a keen eye for data and a passion for evidence-based programs while navigating the complex intersection of science, regulation, and patient safety. Shirley brings rigor, integrity, and a touch of practical wit to every project she tackles. She enjoys diving into the details, staying curious, and asking the questions that lead to smarter answers. Whether orchestrating multi-site trials or writing protocols, she's driven by a belief that good research and data lead to better care—and ultimately, healthier lives.

To learn more about Floreo, visit floreovr.com.

About Floreo
Floreo's vision is a world that is open and accessible for every neurodiverse person. Its mission is to create the first behavioral therapy metaverse, a virtual world that is safe for learners, equipping them with skills and tools they can apply in their everyday lives. Floreo has developed a virtual reality platform that teaches social, behavioral, communication, and life skills for individuals with Autism Spectrum Disorder, ADHD, anxiety, and other neurodiverse conditions. For more information, please visit floreovr.com.

SOURCE Floreo